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ABSTRACT
Background
There have been increasing concerns regarding the safety and efficacy of neuroleptics in
people with dementia, but there are very few long-term trials to inform clinical practice. The
aim of this study was to determine the impact of long-term treatment with neuroleptic agents
upon global cognitive decline and neuropsychiatric symptoms in patients with Alzheimer
disease.
Methods and Findings
Design: Randomised, blinded, placebo-controlled parallel two-group treatment discontinuation
trial.
Setting: Oxfordshire, Newcastle and Gateshead, London and Edinburgh, United Kingdom.
Participants: Patients currently prescribed the neuroleptics thioridazine, chlorpromazine,
haloperidol trifluoperazine or risperidone for behavioural or psychiatric disturbance in
dementia for at least 3 mo.
Interventions: Continue neuroleptic treatment for 12 mo or switch to an identical placebo.
Outcome measures: Primary outcome was total Severe Impairment Battery (SIB) score.
Neuropsychiatric symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
Results: 165 patients were randomised (83 to continue treatment and 82 to placebo, i.e.,
discontinue treatment), of whom 128 (78%) commenced treatment (64 continue/64 placebo).
Of those, 26 were lost to follow-up (13 per arm), resulting in 51 patients per arm analysed for
the primary outcome. There was no significant difference between the continue treatment and
placebo groups in the estimated mean change in SIB scores between baseline and 6 mo;
estimated mean difference in deterioration (favouring placebo)  0.4 (95% confidence interval
[CI] 6.4 to 5.5), adjusted for baseline value (p¼0.9). For neuropsychiatric symptoms, there was
no significant difference between the continue treatment and placebo groups (n¼ 56 and 53,
respectively) in the estimated mean change in NPI scores between baseline and 6 mo;
estimated mean difference in deterioration (favouring continue treatment) 2.4 (95% CI 8.2 to
3.5), adjusted for baseline value (p ¼ 0.4). Both results became more pronounced at 12 mo.
There was some evidence to suggest that those patients with initial NPI   15 benefited on
neuropsychiatric symptoms from continuing treatment.
Conclusions
For most patients with AD, withdrawal of neuroleptics had no overall detrimental effect on
functional and cognitive status. Neuroleptics may have some value in the maintenance
treatment of more severe neuropsychiatric symptoms, but this benefit must be weighed
against the side effects of therapy.
Trial registration: Cochrane Central Registry of Controlled Trials/National Research Register
(#ISRCTN33368770).
The Editors’ Summary of this article follows the references.
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Worldwide, there are 25 million people with dementia [1],
the majority of whom have Alzheimer disease (AD). It is a
devastating illness that results in a progressive decline in
cognitive ability and functional capacity, causes immense
distress to patients, their carers, and families, and has an
enormous societal impact. Currently the most frequent
treatment issue for people with AD presenting to clinical
services remains the management of neuropsychiatric symp-
toms, such as aggression, agitation, and psychosis. Over 90%
of people with dementia develop these symptoms at some
point during their illness [2]. The symptoms are frequently
distressing for the patients who experience them [3] and
problematic for their caregivers [4], in whom they are
associated with clinically signiﬁcant depression [5]. In
addition, they are often the precipitant for institutional care
[6].
Neuroleptics are widely used as the ﬁrst-line pharmaco-
logical approach to treat these neuropsychiatric symptoms.
Efﬁcacy has been examined in eight randomized, placebo-
controlled trials with typical neuroleptics [7,8] and 18
placebo-controlled trials with atypical neuroleptics [9–11].
The strongest evidence of efﬁcacy is for risperidone, for
which there are ﬁve published trials indicating a modest but
signiﬁcant diminution in aggression compared to placebo,
but limited evidence of beneﬁt for other neuropsychiatric
symptoms [9–11]. However, given that in the US and Europe,
up to 60% of people with dementia residing in care facilities
are prescribed neuroleptics (e.g., [12,13]) for median periods
of greater than a year [14,15], the pivotal question is whether
longer-term therapy with atypical neuroleptics confers any
treatment beneﬁt. There are only two placebo-controlled
trials of a neuroleptic for more than 14 wk, and neither
showed signiﬁcant efﬁcacy of neuroleptic treatment for
neuropsychiatric symptoms [16,17]. Similarly, longitudinal
cohort studies [18] and placebo-controlled neuroleptic with-
drawal studies [14,15,19] do not indicate beneﬁt from
neuroleptic therapy. However, all of the withdrawal studies
continued for 3 mo or less, leaving some uncertainty
regarding long-term symptom outcome. In addition, the
largest study did suggest a beneﬁt for treatment with atypical
neuroleptics in people with scores greater than 14 on the
Neuropsychiatric Inventory (NPI) [15].
Any beneﬁcial effects of neuroleptics in people with AD
must be weighed against the short- and long-term adverse
effects which, according to meta-analyses, include parkinson-
ism, sedation, oedema, chest infections, stroke (odds ratio
2.5–3) and mortality (odds ratio 1.5–1.7) [7–11,20–22]. Addi-
tional evidence has also highlighted accelerated cognitive
decline as an important potential negative consequence of
prolonged use of neuroleptics [16,23]. A meta-analysis [17]
has conﬁrmed this observation, indicating 0.7 of a Mini
Mental State Examination (MMSE) point (95% conﬁdence
interval [CI] 0.38 to 1.09) greater decline over 6–12 wk in
neuroleptic-treated patients compared to those treated with
placebo, which appears modest but represents a doubling in
the expected rate of cognitive deterioration over this period.
In the US the Food and Drug Administration [22] has
warned about the risk of increased mortality and stroke with
neuroleptics in people with dementia, and most practice
guidelines recommend nonpharmacological approaches as
the ﬁrst-line treatment for agitation and other neuropsychi-
atric symptoms (e.g., [24]). However, there is still considerable
debate as to the place of neuroleptics in the management of
severe and distressing symptoms that are intractable to other
treatment approaches, especially when there is potential risk
to the patient or to others.
The main aim of the trial was to determine whether
ongoing treatment with neuroleptics accelerates cognitive
decline in people with AD. We additionally sought to
determine whether ongoing treatment with neuroleptics
confers any beneﬁt for the long-term maintenance treatment
of neuropsychiatric symptoms in people with AD.
Methods
Participants
Participants were patients in Oxfordshire, South Birming-
ham, Newcastle and Gateshead, London and Edinburgh
prescribed the neuroleptics thioridazine, chlorpromazine,
haloperidol, triﬂuoperazine or risperidone for behavioural or
psychiatric disturbance in dementia for at least 3 months.
Participants had to meet all inclusion criteria. The
inclusion criteria were (a) patient lived in a nursing or
residential home; (b) patient fulﬁlled the NINCDS/ADRDA
criteria for possible or probable AD [25]; (c) patient had
either a MMSE [26] score . 6 or a Severe Battery Impairment
[27] score . 30; and (d) patient was taking at least 10 mg
chlorpromazine equivalents (CPZe) of a typical neuroleptic or
at least 0.5 mg daily of risperidone.
The exclusion criteria were (a) patient was unable to
complete primary outcome measures at baseline assessment;
(b) clinician responsible for care or study clinician considered
that the patient suffered from any physical condition—
including marked extrapyramidal disorder—that would have
made participation in the trial distressing or likely to increase
suffering; (c) patient was currently taking thioridazine and
showing a prolonged QTc on electrocardiogram [28,29]; (d)
the patient was likely to be unable to take capsules.
Ethics
Two caregivers of people with Alzheimer’s disease were
closely involved in the development of the protocol, which
was peer reviewed through the auspices of the Alzheimer’s
Research Trust (Cambridge, UK). As this was a multicentre
trial, the study was in the ﬁrst instance reviewed and
approved by a properly constituted Multi-Centre Research
Ethics Committee (the North of England MREC). Subsequent
site-speciﬁc approval was then granted by properly consti-
tuted Local Research Ethics Committees at each of the
participating centres. All Ethics Committees were conducted
under the auspices of the Central Organization of Research
Ethics Committees (COREC, now the National Research
Ethics Service UK, http://www.nres.npsa.nhs.uk/).
Consent
Potentially suitable individuals residing in care facilities,
their next of kin, and staff within the care facilities were
provided with comprehensive information about the study.
Those wishing to take part were invited to participate. If the
potential participant had adequate capacity, the individual
him- or herself was asked to complete the written study
consent procedures. In these circumstances, the next of kin
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guardian, usually the manager of the care facility) was also
asked to provide written assent to participation. If partic-
ipants did not have adequate capacity, then written assent
from the next of kin and agreement as far as could be
ascertained from the potential participant were obtained and
considered appropriate to enable participation. This proce-
dure was fully approved by the MREC, and was standard
procedure in clinical trials involving vulnerable adults in the
UK, until subsequent legislative changes (Mental Capacity Act
2005), introduced after the current study, enabled consent to
be provided by a caregiver.
Interventions
Participants were randomised in equal numbers either to
continue neuroleptic treatment for 12 mo or to switch to
placebo. Three ﬁxed dosages, named respectively (a) very low;
(b) low; and (c) high, were chosen for each of the permitted
neuroleptic drugs to correspond as near as possible to the
dose the patient was being prescribed prior to trial entry
(Table 1).
Each of the neuroleptics was overencapsulated to conceal
the identity of the contents. Placebo capsules were identical
to the overencapsulated neuroleptics, but contained only
inert ﬁller. The respective treatments were maintained at the
same ﬁxed dose throughout the 12 mo treatment period of
the trial.
Objectives
The primary aim of this study was to determine whether
treatment with neuroleptic agents is associated with an
accelerated rate of cognitive decline in dementia. Secondary
objectives were: (a) to examine the impact of neuroleptics on
function and other cognitive outcomes; (b) to determine
whether discontinuing neuroleptics was associated with an
exacerbation of neuropsychiatric symptoms, both overall and
in people with NPI scores above and below 14 [15]; (c) to
examine the impact on parkinsonism; and (d) to determine
the impact on global clinician rated outcome.
Outcomes
Primary outcomes. The primary outcome was the total SIB
score [27] (change from baseline to 6 mo). This is a well-
validated instrument designed to evaluate global cognitive
functioning in individuals who are too impaired to complete
standard neuropsychological tests. There are 40 questions in
the SIB, assessing social interaction, memory, orientation,
language, attention, praxis, visuospatial ability, construction,
and orienting to name. A total score is obtained by summing
all questions and ranged from 0 to 100. A higher score
indicates higher cognitive ability.
Secondary outcomes.
1. Standardised Mini Mental State Examination (SMMSE)
[26]: A widely used instrument for assessing cognitive mental
status. It assesses orientation, attention, immediate and short-
term recall, language, and the ability to follow simple verbal
and written commands. The maximum total score is 30. A
higher total score indicates higher cognitive function. A
standardized approach to the administration has been
published and was adopted in the current study [26].
2. FAS test of Verbal Fluency [30]: A verbal ﬂuency test for
which the total score is presented as the sum of all acceptable
words generated.
3. Bristol Activities of Daily Living Scale (BADLS) [31]: A 20-
item questionnaire to measure daily living abilities, speciﬁ-
cally in patients with dementia. The maximum score is 60.
4. Shefﬁeld Test for Acquired Language Disorders (STALD)
[32]: Developed as a nonspecialist clinical aid to help identify
dysphasia. The test assesses receptive and expressive skills. It
gives a total score ranging from 0 to 26.
5. NPI [33]: A caregiver-administered questionnaire that
assesses 12 behaviours of patients on the basis of frequency
and severity: delusions, hallucinations, agitation/aggression,
depression/dysphoria, anxiety, elation/euphoria, apathy/indif-
ference, disinhibition, irritability, aberrant motor behaviour,
night-time behaviours, and appetite/eating behaviours. Each
behaviour is scored by multiplying the frequency and severity
(i.e., frequency 3 severity); the higher the score, the greater
the neuropsychiatric impairment. A total score can be
calculated by summing the scores of all behaviours (range 1
to 144). Lower scores indicate less frequent/severe.
6. Functional Assessment Staging (FAST) [34]: Has seven
main stages that consist of physical and instrumental active
daily living, which are intended to project the progression of
loss of function in patients with dementia.
7. Modiﬁed Uniﬁed Parkinson’s Disease Rating Scale (M-
UPDRS): A modiﬁcation of the full UPDRS, to focus only the
items that were independent of cognitive function [35]. A
score of 8 or more indicates signiﬁcant parkinsonism [35].
8. Clinician’s Global Impression of Change (CGIC): A
widely used and validated rating scale [36] based on the
health-care provider’s ‘‘general clinical impressions’’ with or
w i t h o u tt h ei n f o r m a n ti n p u t( i . e . ,f a m i l ym e m b e r s ) .I t
evaluates global function and is scored from 1 (very much
improved) to 7 (very much worsened).
For scales requiring an informant, the information was
provided by a nurse or professional caregiver who had
regular contact with the individual, usually the key worker. As
far as possible, the same informant provided information for
subsequent assessments. The outcome assessment schedule is
summarised in Table 2.
Although the study was of 12 mo treatment (or discontin-
uation), our primary focus was the progression of cognitive
impairment at the 6 mo assessment. This schedule was
predetermined in view of the frailty and predicted high
mortality of this patient population.
Sample Size
The planned sample size of this trial was 110 patients per
treatment group. In the absence of data from randomized
clinical trials to inform power calculations at the time the
protocol was developed, this calculation was undertaken
using two different approaches. First, based upon the
Table 1. Fixed Dosage Regimens for the Respective Neuroleptics
Neuroleptic Very Low Low High
Risperidone 0.5 mg once daily 0.5 mg twice daily 1 mg twice daily
Chlorpromazine 12.5 once daily 12.5 twice daily 25 twice daily
Trifluoperazine 0.5 mg once daily 0.5 mg twice daily 1 mg twice daily
Haloperidol 0.75 mg once daily 0.75 mg twice daily 1.5 twice daily
doi:10.1371/journal.pmed.0050076.t001
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as decline greater than the mean expected cognitive decline
of four points per year on the MMSE), in 50% of patients
continuing on neuroleptics versus 30% on placebo, allowing
for a dropout rate of 15%–20%. Second, using a generic
approach [37], the same sample size gives 80% power to the
5% level of signiﬁcance to detect an effect size of 0.43
(regarded conservatively as a medium effect size). As we
expected the SIB to be a more sensitive measure than MMSE,
it was anticipated that the sample size would have more than
sufﬁcient power to detect a clinically important difference.
Randomisation
Randomisation was performed centrally at the Centre for
Statistics in Medicine in Oxford (CSMO), using dedicated
computer software (MINIM). The clinician responsible for
randomisation of a patient faxed a randomisation form to the
CSMO (or sent e-mail in exceptional circumstances) and
provided details appropriate and sufﬁcient for establishing
eligibility. If a patient was eligible and informed consent/assent
had been obtained and baseline assessments had been
completed, the patient was randomised by the statistician
either to continue taking medication or to discontinue
(placebo group). The statistician directly communicated the
allocation to the relevant trial pharmacy, ensuring conceal-
ment. The randomisation programme included a minimisation
algorithm to ensure balanced allocation of participants across
the intervention groups for the following important prognos-
tic factors: presence or absence of extrapyramidal signs (EPS);
visual hallucinations and delusions; use of cholinesterase
inhibitors (y/n); SMMSE score (,6/ 6); and current neuro-
leptic medication (atypical/typical). The ﬁrst 22 patients (10%
of the target sample size) were allocated randomly to avoid
predictability at the outset. These allocations were computer
generated using block randomisation (block sizes of two and
four) using Stata version 7 software (ralloc.ado v3.2.3
subroutine) [38]. Subsequently, the minimisation algorithm
was applied with an allocation ratio that was not fully
deterministic. The statistician carrying out the randomisation
had no direct contact with patients and allocation was,
therefore, totally independent of patient recruitment.
Blinding
The clinicians, those administering the trial medication,
the caregivers, the relatives, the patients themselves, and
those assessing the outcomes were all blinded to treatment
allocation.
Statistical Methods
We used SPSS (release 12.0.1) to enter and manage data,
and Stata (release 9.2) for analysis. Demographic factors and
clinical characteristics were summarised with counts (percen-
tages) for categorical variables, mean (standard deviation
[SD]) for normally distributed continuous variables, or
median (interquartile [IQR] or entire range) for other
continuous variables. We restricted comparative analysis to
those patients who started allocated treatment and had at
least one assessment after randomisation, and participants
were analysed in the groups to which they were allocated.
Primary analysis was performed on patients with complete
data at both baseline and week 26, including those who did
not adhere to the protocol (e.g., those who never started
treatment but for whom we had complete data). As the trial
was conducted with masking of treatments, knowledge of
allocation could not have contributed to drop-outs before or
after treatment, so that exclusion of such patients did not
impart bias. For the primary analysis, we summarised the
change in the severe impairment battery (i.e., SIB at 6 mo  
SIB at baseline) score from baseline to 6 mo using the mean
and SD. To establish the magnitude and direction of the
treatment effect, we used analysis of covariance (ANCOVA)
to compare the two groups, giving the mean difference (in
change in SIB from baseline to 6 mo) between groups (plus
95% CIs and p-values) with adjustment for baseline value. An
additional ANCOVA was performed with adjustment for the
minimisation factors, as well as geographical centre, in
addition to the treatment contrast and baseline values.
Changes in secondary outcomes were summarised and
compared similarly.
For non-normally distributed continuous outcomes, we
performed nonparametric Wilcoxon rank-sum tests to inves-
tigate differences between the treatment groups.
Prespeciﬁed sensitivity analyses were carried out to
examine the robustness of conclusions to different assump-
tions about departures from randomised policies, dependent
on the availability of data and the particular set of circum-
stances, namely:
1. Imputation is a method of ‘‘ﬁlling in’’ missing data with
plausible values to give a completed dataset. Multiple
imputation replaces each missing value with a set of plausible
values that represent the uncertainty about the right value to
Table 2. Outcome Assessment Schedule
Assessment Pretreatment Screening Baseline 1 Month 3 Months 6 Months 12 Months
SIB — U —— UU
SMMSE UU U — UU
FAS — U —— UU
BADLS — UU— UU
STALD — U —— UU
NPI UU U U U U
FAST — U —— UU
M-UPDRS — U —— UU
CGIC — — — — UU
doi:10.1371/journal.pmed.0050076.t002
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times to generate m complete datasets. Then the m complete
datasets are analysed by using standard statistical analyses,
and ﬁnally, the results from the m complete datasets are
combined to produce inferential results. Variables that were
included in the imputation model were all assessments of SIB,
NPI, FAS, SMMSE, BADLS, STALD-receptive, STALD-ex-
pressive, FAST, and CGIC collected at baseline, 6, and 12 mo.
Other baseline covariates that were also included in the
imputation model were allocated treatment group, sex,
centre, presence of signiﬁcant EPS, visual hallucinations or
delusions, age at randomisation, type of neuroleptic drug at
baseline, and whether the participant was taking cholinester-
ase inhibitors at trial entry.
2. In order to test the robustness of the SIB result, we
limited a sensitivity analysis to those patients for whom the
risk of possible ﬂoor and ceiling effects was smallest, i.e., SIB
baseline cut-off values   40 but   90. Prespeciﬁed subgroup
analyses were carried out on change in SIB and change in
NPI. We performed the test of interaction, i.e., examined
whether the treatment effects were consistent across sub-
groups. The subgroups investigated were (a) type of neuro-
leptic (atypical versus typical)—it made clinical sense to
examine whether the type of neuroleptic (atypical versus
typical) at baseline made a difference since, if one type was
more harmful than the other, then discontinuation would
beneﬁt those patients more; (b) baseline NPI (  14 versus  
15)—we intended to look at consistency of treatment effect in
relation to baseline NPI (  14 versus 15 or more) in an
attempt to replicate Ballard et al. 2004 [15]; and (c) centre
effects (Newcastle versus Oxford versus London/Edinburgh).
London and Edinburgh were grouped together because only
a small number of participants were recruited from Edin-
burgh, and all were assessed by the London-based research-
ers.
Study Governance
A three-person independent data-monitoring committee
(DMC) was charged with overseeing patient safety. Its remit
included prompt review of serious adverse events and a
comprehensive review of all adverse events based upon
interim data reports. The remit also required advice
regarding any new or emerging information on the safety
of the study treatments. If required, the DMC would make
recommendations to the trial steering group and the sponsor
about the safe continuation of the trial and any issues of
concern. These decisions relied upon the independence and
expertise of the DMC members and did not follow any strict
‘‘stopping rules.’’
Results
Participant Flow
The ﬁrst patient was randomised in October 2001 and the
last in December 2004. 165 patients were randomised (83 to
continue treatment and 82 to placebo, i.e., discontinue
treatment), of whom 128 (78%) commenced treatment (64
continue/64 placebo) (Figure 1). Of those, 26 were lost to
follow-up (13 per arm), resulting in 51 patients per arm
analysed for the primary outcome. Of those (102 total), 77
remained on allocated treatment at 6 mo follow-up (40
continue/37 placebo). A further 22 participants withdrew
between 6 and 12 mo follow-up (Figure 1). Over the full 12 mo
of the study 47 people did not complete follow-up. Of these
individuals 21 died and a further 26 (55%) stopped the
allocated treatment. Baseline demographic and clinical
characteristics were evenly balanced across the two groups
(Tables 3 and 4). The majority of the participants were taking
risperidone/placebo risperidone (n ¼ 101) or haloperidol/
placebo haloperidol (n ¼ 43) at baseline. A full breakdown of
the neuroleptic drugs used in the study is given in Table 5.
Primary Outcome—Severe Impairment Battery
There was no signiﬁcant difference between the continue
treatment and placebo groups (n ¼ 51 in both arms) in the
estimated mean change in SIB scores between baseline and 6
mo (Figure 2; Table 6), 5.7 points (SD 14.2) deterioration for
the placebo group, and a 6.2 (SD 16.0) deterioration for the
continue treatment group; estimated mean difference in
deterioration (favouring placebo)  0.4 (95% CI  6.4 to 5.5),
adjusted for baseline value (p ¼ 0.9).
Secondary Outcomes
Neuropsychiatric symptoms. For the NPI, there was no
signiﬁcant difference between the continue treatment and
placebo groups (n ¼ 56 and 53, respectively) in the estimated
mean change in NPI scores between baseline and 6 mo, 4.5
points (SD 17.6) deterioration for the placebo group
compared to a 1.3 (SD 15.5) deterioration for the continue
treatment group; estimated mean difference in deterioration
(favouring continue treatment)  2.4 (95% CI  8.2 to 3.5),
adjusted for baseline value (p ¼ 0.4). In patients with NPI
scores   14 (Figure 3) the change in NPI over 6 mo was very
similar in the neuroleptic and placebo groups (estimated
difference 0.49, 95% CI  5.63 to 6.60), whereas in the people
with NPI scores . 14 there was a ﬁve-point, albeit non-
signiﬁcant, advantage for people continuing to receive
neuroleptics (estimated difference  5.33, 95% CI  15.82 to
5.17).
Cognition, language, and function. For the SMMSE, there
was no signiﬁcant difference between the continue treatment
and placebo groups (n ¼ 44 and 40, respectively) in the
estimated mean change in SMMSE scores between baseline
and 6 mo (Table 6), 1.0 points (SD 4.2) deterioration for the
placebo group, and a 1.8 (SD 3.6) deterioration for the
continue treatment group; estimated mean difference in
deterioration (favouring placebo)  1.0 (95% CI  2.7 to 0.7),
adjusted for baseline value (p ¼ 0.2). For the BADLS, likewise
there was no signiﬁcant difference between the continue
treatment and placebo groups (n¼54 and 52, respectively) in
the estimated mean change in BADLS scores between
baseline and 6 mo, 0.2 points (SD 7.2) worsening for the
placebo group, and a 1.8 (SD 8.9) worsening for the continue
treatment group; estimated mean difference in improvement
(favouring placebo) 1.7 (95% CI  1.2 to 4.6), adjusted for
baseline value (p ¼ 0.2).
For the STALD (receptive skills), once again there was no
signiﬁcant difference between the continue treatment and
placebo groups (n ¼ 34 and 39 respectively) in the estimated
mean change in STALD (receptive skills) scores between
baseline and 6 mo, 0.3 points (SD 2.1) deterioration for the
placebo group, and a 0.5 (SD 1.7) deterioration for the
continue treatment group; estimated mean difference in
deterioration (favouring placebo)  0.2 (95% CI  1.1 to 0.6),
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no signiﬁcant difference between the continue treatment and
placebo groups (n ¼ 34 and 39, respectively) in the estimated
mean change in receptive language scores between baseline
and 6 mo. For expressive language there was no signiﬁcant
difference of placebo compared to the treatment group;
estimated mean difference (favouring placebo)  1.0 (95% CI
 2.0 to 0.04), adjusted for baseline value (p ¼ 0.06).
However, for the FAS, there was strong evidence, i.e., a
highly signiﬁcant difference between the continue treatment
and placebo groups (n ¼ 34 and 31, respectively) in the
estimated mean change in FAS totals between baseline and 6
mo. There was 0.6 points (SD 6.2) improvement for the
placebo group compared to a 3.2 (SD 6.6) deterioration for
the continue treatment group; estimated mean difference
(favouring placebo)  4.5 (95% CI  7.3 to  1.7), adjusted for
baseline value (p ¼ 0.002).
Parkinsonism. For the M-UPDRS, there was a slight but
nonsigniﬁcant difference between the continue treatment
and placebo groups (n ¼ 41 and 43, respectively) in the
estimated mean change in M-UPDRS scores between baseline
and 6 mo, 0.4 points (SD 3.2) improvement for the placebo
group compared to a 0.8 (SD 4.1) deterioration for the
continue treatment group; estimated mean difference (fa-
vouring placebo) 1.1 (95% CI  0.4 to 2.6), adjusted for
baseline value (p ¼ 0.1).
Global Outcome
For the change in FAST and CGIC, there was no evidence
whatsoever of any differences between the continue treat-
Figure 1. Flow of Participants through the Trial
doi:10.1371/journal.pmed.0050076.g001
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both).
Prespecified Sensitivity Analyses
Imputed values were included for 12 participants, six in
each treatment arm. These individuals had similar character-
istics to the overall trial population, but as would be expected
for participants unable to complete the trial, at baseline they
were more cognitively impaired (SIB 6 SD, 68.1 6 22.3 versus
74.4 6 21.9) and had higher levels of neuropsychiatric
symptoms (NPI 6 SD, 22.2 6 14.8 versus 16.0 6 13.9) than
patients who subsequently completed the 6 month assess-
ments. The results for SIB (mean difference 2.1, 95% CI 8.8
to 4.6, p ¼ 0.5), NPI, SMMSE, UPDRS, BADLS, STALD, and
FAS all remained consistent when missing data were replaced
using multiple imputation techniques. In addition, the result
for sensitivity analysis of SIB excluding participants whose
baseline SIB was , 40 or . 90, i.e., excluding patients unlikely
to beneﬁt from treatment (mean difference 0.2, 95% CI 9.2
to 8.9, p ¼ 0.9) was again consistent with the primary result.
Prespeciﬁed subgroup analysis. There was no evidence of
any interaction between treatment group and the various
subgroups (Figures 3 and 4).
Post-Hoc Additional Exploratory Sensitivity Analysis
Given that a substantial proportion of patients did not
actually start allocated treatment (;22%), we decided to
examine the robustness of results by performing an analysis
with all data available. In addition, according to the protocol,
all patients with SMMSE , 6 at pretrial screening were not
required to complete SMMSE and FAS at any subsequent
assessments; however, some measures were collected during
the follow-up. Therefore, additional sensitivity analysis was
performed on SMMSE and FAS to assess if results remained
consistent when these measures were included. Once again,
there were no substantive differences between the primary
and sensitivity analyses, i.e., the results are very robust.
Although not speciﬁed in the original analysis plan, to
avoid omitting potentially important clinical differences,
additional descriptive data were also obtained regarding
emergent delusions and agitation in participants who did not
have these symptoms at baseline. The pattern of emergent
symptoms appeared similar in the two treatment arms at 1, 3,
and 6 mo assessments, respectively, for both delusions
(neuroleptics 14%, 16%, 5% versus placebo 5%, 8%, 13%)
and agitation (neuroleptics 17%, 23%, 32% versus placebo
23%, 26%, 34%).
12 Month Assessment Data
Analysis at 12 mo was limited to the two main outcomes,
cognitive function and neuropsychiatric features, given the
large amount of missing data. There was no signiﬁcant
difference between the continue treatment and placebo
groups (n ¼ 28 and 27, respectively) in the estimated mean
change in SIB scores between baseline and 12 mo, although
there was a clinically important but not statistically signiﬁ-
cant numerical advantage of 8 points for the placebo group—
8.5 points (SD 13.4) deterioration in the placebo group, and a
16.5 (SD 23.1) deterioration in the continue treatment group;
estimated mean difference in deterioration (favouring
placebo)  8.4 (95% CI  18.6 to 1.7), adjusted for baseline
value (p ¼ 0.1).
For the NPI, there was, however, a signiﬁcant difference
between the continue treatment and placebo groups (n ¼ 28
and 31 respectively) in the estimated mean change in NPI
scores between baseline and 12 mo, with 11.4 points (SD 17.7)
Table 3. Demographic and Clinical Characteristics and Assessments at Baseline (All Patients Randomized)
Baseline Characteristics or Assessment Statistics Continue Treatment (n ¼ 83) Placebo (n ¼ 82)
Women No. (%) 64 (77.1) 62 (75.6)
Age Mean (SD) [range], y 84.8 (7.0) [68.3–100.2] 84.9 (6.1) [67.0–100.6]
Significant EPS No. (%) 39 (47.0) 39 (47.6)
Visual hallucinations No. (%) 10 (12.0) 10 (12.0)
Delusions No. (%) 27 (32.5) 27 (32.9)
Taking cholinesterase inhibitor No. (%) 2 (2.4) 3 (3.7)
Taking atypical neuroleptic prerandomisation No. (%) 57 (68.7) 58 (70.7)
SMMSE Mean (SD) (no. of patients) 11 (6) (n ¼ 83) 11 (5) (n ¼ 82)
No. (%) scoring below 6 16 (19.3) 14 (17.1)
SIB Mean (SD) (no. of patients) 71.1 (22.7) (n ¼ 75) 73.8 (20.7) (n ¼ 71)
Median (IQR) 77 (58–91) 80 (63–92)
NPI Mean (SD) (no. of patients) 17.4 (14.6) (n ¼ 75) 15.8 (11.3) (n ¼ 70)
Median (IQR) 15 (5–24) 14 (6–24)
FAST Mean (SD) (no. of patients) 5.7 (0.8) (n ¼ 72) 5.5 (0.8) (n ¼ 72)
Median (IQR) 6 (6–6) 6 (5–6)
M-UPDRS Mean (SD) (no. of patients) 2.7 (3.8) (n ¼ 64) 2.7 (3.9) (n ¼ 64)
No (%) scoring 8 or more 6 (9.4) 10 (15.6)
BADLS Mean (SD) (no. of patients) 18.5 (9.0) (n ¼ 73) 17.9 (9.5) (n ¼ 71)
Median (IQR) 19 (12–24) 16 (12–23)
STALD (receptive skill) Mean (SD) (no. of patients) 3.8 (1.9) (n ¼ 59) 4.4 (2.2) (n ¼ 58)
Median (IQR) 4 (3–5) 5 (5–6)
STALD (expressive skill) Mean (SD) (no. of patients) 6.3 (3.0) (n ¼ 59) 7.2 (2.8) (n ¼ 58)
Median (IQR) 7 (4–9) 8 (5–10)
FAS Mean (SD) (no. of patients) 8.4 (7.3) (n ¼ 48) 10.9 (7.9) (n ¼ 45)
Median (IQR) 7 (3–13) 10 (5–14)
doi:10.1371/journal.pmed.0050076.t003
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22.1) deterioration for the continue treatment group;
estimated mean difference in deterioration (favouring con-
tinue treatment)  10.9 (95% CI  20.1 to  1.7), adjusted for
baseline value (p¼0.02). A cut-off   14 on the NPI was again
helpful in interpreting the results. For participants with
baseline NPI scores below this threshold, there was no
signiﬁcant difference between treatment groups; estimated
mean difference in deterioration (favouring continue treat-
ment) 5.2 (95% CI 15.8 to 5.4), whereas for individuals with
higher NPI scores there was a signiﬁcant  16.9 point
‘‘advantage’’ for the group who continued neuroleptics
(95% CI  32.5 to  1.2). However, the test of interaction,
although underpowered, was not signiﬁcant (p ¼ 0.2); there-
fore there is no evidence of a statistical interaction.
Discussion
Because of difﬁculties in identifying people with Alzheimer
disease in nursing homes who were taking neuroleptics and
Table 5. Details of Type and Dose of Treatment before Randomisation by Allocated Treatment Group
Prerandomisation Randomised Allocation
Current Treatment—Name of Neuroleptic Dose Continue Treatment (n ¼ 83) Placebo (n ¼ 82)
Chlorpromazine High 0 1
Very low/low 1 1
Haloperidol High 1 0
Very low/low 22 20
Olanzapine High 0 2
Very low/low 4 3
Promazine High 0 0
Very low/low 0 2
Quetiapine High 0 0
Very low/low 1 3
Risperidone High 9 12
Very low/low 43 37
Thioridazine High 0 0
Very low/low 2 0
Trifluoperazine High 0 1
Very low/low 0 0
doi:10.1371/journal.pmed.0050076.t005
Table 4. Demographic and Clinical Characteristics and Assessments at Baseline (Analysis Population)
Baseline Characteristics Statistics Continue Treatment (n ¼ 51) Placebo (n ¼ 51)
Women No. (%) 38 (74.5) 38 (74.5)
Age Mean (SD) [range], y 84.5 (7.7) [68.3–100.0] 84.4 (6.4) [67.0–100.6]
Significant EPS No. (%) 28 (54.9) 28 (54.9)
Visual hallucinations No. (%) 7 (13.7) 6 (11.8)
Delusions No. (%) 21 (41.2) 18 (35.3)
Taking cholinesterase inhibitor No. (%) 1 (2.0) 3 (5.9)
Taking atypical neuroleptic prerandomisation No. (%) 32 (62.8) 37 (72.6)
SMMSE Mean (SD) (no. of patients) 12 (5) (n ¼ 45) 13 (4) (n ¼ 42)
No. (%) scoring below 6 1 (2.2) 1 (2.4)
SIB Mean (SD) (no. of patients) 72.4 (22.9) (n ¼ 51) 76.3 (20.8) (n ¼ 51)
Median (IQR) 78 (50–91) 82 (68–93)
NPI Mean (SD) (no. of patients) 17.2 (15.9) (n ¼ 51) 14.7 (11.5) (n ¼ 50)
Median (IQR) 12 (4–24) 11 (5–23)
FAST Mean (SD) (no. of patients) 5.7 (0.8) (n ¼ 49) 5.4 (0.9) (n ¼ 51)
Median (IQR) 6 (6–6) 6 (4–6)
M-UPDRS Mean (SD) (no. of patients) 2.3 (3.0) (n ¼ 48) 2.3 (3.5) (n ¼ 46)
No (%) scoring 8 or more 3 (6.2) 6 (13.0)
BADLS Mean (SD) (no. of patients) 17.7 (8.5) (n ¼ 50) 16.1 (8.6) (n ¼ 50)
Median (IQR) 19 (12–23) 16 (8–21)
STALD (receptive skill) Mean (SD) (no. of patients) 4.3 (1.7) (n ¼ 39) 4.5 (2.3) (n ¼ 44)
Median (IQR) 4 (3–6) 5 (3–6)
STALD (expressive skill) Mean (SD) (no. of patients) 6.8 (2.8) (n ¼ 39) 7.2 (2.9) (n ¼ 44)
Median (IQR) 7 (5–9) 8 (5–10)
FAS Mean (SD) (no. of patients) 8.6 (6.8) (n ¼ 37) 11.3 (8.8) (n ¼ 32)
Median (IQR) 7 (3–13) 10 (5–16)
doi:10.1371/journal.pmed.0050076.t004
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Neuroleptics in Dementia Patientswere able to complete the rigorous cognitive assessments, the
recruitment target sample size based on the power calcu-
lation was not attained. However, despite this drawback, we
report the largest and longest-duration randomized placebo
controlled trial of neuroleptic discontinuation. To our
knowledge this is the ﬁrst study of this type to evaluate
outcome over 6 mo and beyond.
Treatment with neuroleptics was not associated with
signiﬁcantly greater decline in global cognitive function than
placebo, although there were numerical advantages for the
placebo-treated group on the SIB and the SMMSE (1 point
decrease on SMMSE, 0.4 point decrease on SIB overall, ;3
point decrease on SIB in people with NPI scores   14) at 6
mo, which became more pronounced by month 12, at which
point there was an 8 point advantage on the SIB for the
placebo-treated group, equivalent to approximately 6 mo of
average expected cognitive decline. The failure of these
differences to attain statistical signiﬁcance may be because of
limited statistical power (a type II error), as the magnitude of
difference in change in global cognition between neuro-
leptics and placebo at 6 mo was consistent with the effect size
identiﬁed in a recent meta-analysis [11], and became more
substantial over further follow-up. It would be more usual in
a study of this type to hypothesise equivalence or the absence
of an advantage to the treatment that is being removed, and
there is certainly no evidence at all from these results
suggesting any cognitive advantage favouring antipsychotics.
On secondary cognitive outcomes, there was a signiﬁcant
deterioration in verbal ﬂuency for patients taking neuro-
leptics compared to people receiving placebo, and there was a
nonsigniﬁcant numerical advantage for the placebo-treated
group on the BADLS. There were nonsigniﬁcant numerical
advantages for the placebo group with respect to the severity
of parkinsonism.
There was a marginal nonsigniﬁcant 2.4 point advantage on
the total NPI score for continuing neuroleptic treatment over
the ﬁrst 6 mo of treatment. Using a baseline NPI threshold
 14, previously reported to be predictive of outcome in a 3
mo neuroleptic withdrawal trial [15], the change in NPI did
not differ between the treatment groups. Participants with
baseline NPI scores . 14 had an almost 5 point advantage
(albeit nonsigniﬁcant) if they remained on neuroleptics,
whereas there was no beneﬁt for people with NPI scores
below this threshold. For patients with more severe neuro-
psychiatric symptoms, there were modest beneﬁts at 6 mo
and more substantial advantages at 12 mo, which have to be
weighed against the potential for serious adverse events.
Some of the changes in NPI score are likely to be related to
natural symptom course, or a Hawthorne effect, or regression
to the mean, although there should be no imbalance in these
factors between groups. There were no differences between
groups for global clinician-rated outcome, and in an addi-
tional descriptive evaluation there appeared to be no differ-
ence in emergent delusions or agitation between groups.
In the post-hoc analysis there was no indication of a
difference between people taking typical or atypical neuro-
leptics. The majority of individuals were taking risperidone
or haloperidol, and the number of people taking other drugs
was too small to enable any meaningful comparison. In
particular, it will be important in further work to determine
whether neuroleptics with more prominent antimuscarinic
properties have a more potent impact on cognition in
patients with dementia.
Several studies have demonstrated that psychological
management approaches can replace neuroleptic therapy
Figure 2. Change in Total SIB Score (Baseline to 6 Months) by Treatment Group
doi:10.1371/journal.pmed.0050076.g002
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toms [14,39]; and evidence is emerging that cholinesterase
inhibitors [40] or memantine [41] may be safer, effective
alternatives for some symptoms. The authors of the recent
CATIE study [17], a large, pragmatic, 36-wk placebo-con-
trolled trial of atypical neuroleptics in AD, concluded that
the modest beneﬁts were not sufﬁcient to justify therapy in
the presence of the increased risk of serious adverse events.
Clinicians should certainly try to replace atypical neuro-
leptics with safer management approaches. Taking into
consideration CATIE, the results of 6- to 12-wk placebo-
controlled trials, and our own data, we would suggest that
there is, however, a limited place for atypical neuroleptics in
the maintenance treatment of severe neuropsychiatric
manifestations (particularly aggression) in AD when there is
tangible risk or severe distress, and the symptoms have been
refractory to other treatment approaches.
The magnitude of the impact of neuroleptics upon
cognition, although consistent with a recent meta-analysis,
was considerably less marked than reported in a recent 6 mo
placebo-controlled trial of quetiapine [16]. There are
numerous possible explanations for this difference, although
it may be noted that unlike quetiapine, none of the atypical
antipsychotics used in the current study had substantial
antimuscarinic properties, and it is possible that antimuscar-
inic properties may exacerbate the impact of neuroleptics
upon cognition. Although this is speculative, it is consistent
with a study comparing cognition in patients with AD treated
with either risperidone or olanzapine, where olanzapine
treatment was associated with greater impairment of atten-
tional and executive performance related to anticholinergic
activity [42]. Within the current study there was a signiﬁcant
detrimental impact upon expressive language function, an
important skill to enable social communication and maintain
quality of life in people with AD residing in care facilities.
Further work is needed to examine the effects on different
aspects of cognitive function, to clarify the differential
impact of individual neuroleptic drugs, and to determine
whether the impact upon cognition is sufﬁcient to interfere
with everyday activities.
The results of the current study must be interpreted within
the context of a number of limitations. In particular, the
sample size was much smaller than intended, conferring
limited statistical power, and the number of deaths and
Table 6. Summary of Change from Baseline to 6 Months for Main Outcomes plus Comparative Statistics
Assessment Measure or Category Mean Change (SD)
a Estimated Mean Difference
in Change
b (95% CI)
p-Value
Continue Treatment Placebo
SIB Cognition (n ¼ 51) (n ¼ 51)  0.4 ( 6.4 to 5.5)
c 0.9
 6.2 (16.0)  5.7 (14.2) 1.4 ( 5.4 to 8.1)
d 0.7
NPI Neuropsychiatric symptoms (n ¼ 56) (n ¼ 53)  2.4 ( 8.2 to 3.5)
c 0.4
1.3 (15.5) 4.5 (17.6)  4.3 ( 10.7 to 2.1)
d 0.2
SMMSE Cognition (n ¼ 44) (n ¼ 40)  1.0 ( 2.7 to 0.7)
c 0.2
 1.8 (3.6)  1.0 (4.2)  0.9 ( 2.6 to 0.8)
d 0.3
M-UPDRS Parkinsonism (n ¼ 41) (n ¼ 43) 1.1 ( 0.4 to 2.6)
c 0.1
0.8 (4.1)  0.4 (3.2) 1.3 ( 0.4 to 3.0)
d 0.1
Bristol ADL Function (n ¼ 54) (n ¼ 52) 1.7 ( 1.2 to 4.6)
c 0.2
1.8 (8.9) 0.2 (7.2) 1.0 ( 2.0 to 3.9)
d 0.5
STALD (receptive skill) Receptive language (n ¼ 34) (n ¼ 39)  0.2 ( 1.1 to 0.6)
c 0.6
 0.5 (1.7)  0.3 (2.1)  0.3 ( 1.1 to 0.6)
d 0.5
STALD (expressive skill) Expressive language (n ¼ 34) (n ¼ 39)  1.0 ( 2.0 to 0.04)
c 0.06
 0.6 (1.8) 0.2 (2.5)  0.9 ( 2.0 to 0.2)
d 0.09
FAS Verbal fluency (n ¼ 34) (n ¼ 31)  4.5 ( 7.3 to  1.7)
c 0.002
 3.2 (6.6) 0.6 (6.2)  4.6 ( 7.4 to  1.7)
d 0.002
Change in FAST
e Dementia stage (n ¼ 53) (n ¼ 53) — —
 20 1 —0 . 9
 13 4 ——
03 4 3 2 ——
11 2 8 ——
24 8 — —
CGIC
e Improvement rated by clinician (n ¼ 48) (n ¼ 48) — —
Very much improved 1 (2%) 0 — 0.9
Much improved 3 (6%) 0 — —
Minimally improved 7 (15%) 14 (29%) — —
No change 18 (37%) 14 (29%) — —
Minimally worse 9 (19%) 10 (21%) — —
Much worse 7 (15%) 10 (21%) — —
Very much worse 3 (6%) 0 — —
aPositive change represents improvement (except for NPI, M-UPDRS, and FAST).
bPlacebo is the reference group. Positive difference favours Continue Treatment group (except for NPI, M-UPDRS, and FAST).
cAnalysis of covariance (ANCOVA) adjusted for baseline measurement.
dANCOVA adjusted for baseline measurement (continuous) and minimisation factors centre (categories 1–3, reference Newcastle), significant EPS (reference category absent), visual
hallucinations (reference category absent), delusions (reference category absent), taking cholinesterase inhibitors (reference category no), baseline SMMSE (continuous), and type of
neuroleptic prerandomisation (reference category atypical).
eWilcoxon rank-sum test.
doi:10.1371/journal.pmed.0050076.t006
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the 6 mo follow-up. In addition a sizeable proportion of
patients did not start their allocated treatment for a variety
of reasons, mainly related to frailty and concurrent illnesses.
The sample size achieved was short of the 220 target due
mainly to problems identifying eligible patients, which in
turn led to slow recruitment, bringing on more centres, and
ultimately curtailing recruitment due to a lack of resources.
Given the vulnerability of the study population, a substantial
number of deaths and withdrawals are an almost inevitable
problem to contend with. Probably the only solution would
be to exclude people with profound dementia or with a
certain degree of physical frailty, but this would then
diminish the validity of drawing more general conclusions
from the results. Although it is difﬁcult, therefore, to see how
this problem could have been avoided, the high number of
drop-outs must be considered when interpreting the results.
In addition, the reason for the initial prescription of
neuroleptic drugs was unclear in the majority of instances.
Most prescriptions had been instigated by primary care
Figure 3. Subgroup Analysis (Change in NPI from Baseline to 6 Months)
doi:10.1371/journal.pmed.0050076.g003
Figure 4. Subgroup Analysis (Change in SIB from Baseline to 6 Months)
doi:10.1371/journal.pmed.0050076.g004
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Neuroleptics in Dementia Patientsphysicians and, as a number of the individuals had changed
their primary care physician, or been admitted to a care
facility, or changed care facility since neuroleptics were ﬁrst
prescribed, the clinical indication for the original prescrip-
tion was often lost. Although in many ways this lack of
information is unsatisfactory, it does reﬂect real clinical
practice, so that the population studied and the information
available were representative of what faces clinicians in their
routine practice. As few individuals were under specialist
care, it is unlikely that treatment-refractory symptoms were a
reason for neuroleptic use in most of the participants. The
data regarding outcome and the baseline severity of
symptoms do, however, provide a useful basis for clinical
decisions. It is possible that the proﬁle of the original
symptoms for which the neuroleptics were prescribed may
have inﬂuenced outcome, but this possibility could practically
be investigated only in people with neuroleptic prescriptions
of shorter duration, for which the presenting symptoms
would be easier to ascertain.
Conclusion
For most patients with AD, withdrawal of neuroleptics had
no overall detrimental effect on functional and cognitive
status and by some measures improved functional and
cognitive status. Neuroleptics may have some value in the
maintenance treatment of more severe neuropsychiatric
symptoms, but this possibility must be weighed against the
unwanted effects of therapy. The current study helps to
inform a clinical management strategy for current practice,
but the considerable risks of maintenance therapy highlight
the urgency of further work to ﬁnd, develop, and implement
safer and more effective treatment approaches for neuro-
psychiatric symptoms in people with AD.
Supporting Information
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Editors’ Summary
Background The number of people with dementia (currently 25 million
worldwide) is expected to increase by 5 million each year. The risk of
dementia, including Alzheimer disease, increases sharply with age:
Alzheimer’s Disease International estimates that 1.4% of people 65–69
have dementia, whereas almost a full quarter of those over the age of 85
years are affected. Almost all older dementia patients will experience,
along with the cognitive and functional decline typical of the illness,
some neuropsychiatric symptoms. These symptoms can include agita-
tion, aggression, and psychosis, and are often devastating for the older
patient and his or her family and caregiver. Managing these symptoms is
often a prime concern for health-care providers and families. Neuro-
leptics (sometimes called antipsychotics) are the class of drugs often
used to manage or control neuropsychiatric problems, but there have
been questions about their safety and appropriateness. Safety concerns
involve risk of stroke, parkinsonism, sedation, edema, and chest
infections but also include a worsening of cognitive decline with
prolonged use of neuroleptics.
Why Was the Study Done? Previous studies on the effectiveness and
safety of neuroleptics in older people have been short term. Ballard and
colleagues wanted to study over a longer period of time the impact of
neuroleptic drugs on elderly patients with dementia. Specifically, they
wanted to know if being on a neuroleptic was associated with more
cognitive decline than coming off the drug. They also wanted to
investigate whether discontinuing the drug exacerbated any neuro-
psychiatric symptoms, Parkinson disease-like symptoms, or other func-
tional, language, and cognition difficulties frequently associated with
dementia.
What Did the Researchers Do and Find? The researchers recruited
older patients with Alzheimer disease from across England who had
been on neuroleptics for at least three months. They randomised
patients to one of two groups: the first group continued taking the same
neuroleptic at the same dosage level while the second group was
switched to an identical-looking placebo. The researchers assessed the
patients’ cognitive status and neuropsychiatric symptoms upon their
entry into the study. Six and 12 months later the researchers assessed
any cognitive decline and the level of neuropsychiatric and other
problems that patients were experiencing.
At both 6 and 12 months, the researchers found that there were no
differences between the two groups (continued treatment and placebo)
in terms of cognitive decline. The placebo group may have had less
cognitive decline, but this was not statistically significant. They also
found no overall differences between the two groups in the change in
the number of neuropsychiatric symptoms over these time periods.
Patients with severe neuropsychiatric problems at the outset of the trial
did better on continued neuroleptic therapy, but this advantage was not
statistically significant. There was a significant decline on the verbal
fluency language tests among the patients who continued on their
neuroleptic.
What Do these Findings Mean? The researchers report perhaps the first
trial of this duration on continued versus withdrawn neuroleptic
treatment among older dementia patients. The findings do not indicate
any benefit of continuing neuroleptic therapies in older patients on
either cognitive or neuropsychiatric outcomes. The researchers conclude
that neuroleptics, with their known safety issues, should not be used as
first-line treatment to manage problems such as agitation or aggression.
For older dementia patients whose neuropsychiatric symptoms are not
remedied by nonpharmaceutical treatments, the researchers advise
caution. More studies are urgently needed to find better solutions to
help older patients with dementia who have agitation, aggression, and
psychosis.
Additional Information Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050076.
  Alzheimer’s Disease International is an umbrella organisation of
organisations worldwide
  The Alzheimer’s Research Trust in the UK is a charity funding research
to cure or prevent dementias
  The US National Institutes of Aging has information on Alzheimer
Disease in English and Spanish
  Two governmental regulatory agencies—the Medicines and
Healthcare Products Regulatory Agency in the UK and the Food and
Drug Administration in the US—offer information about antipsycho-
tics in people with dementia
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